Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle.

Anticancer research·2024
Same author

Sickle Cell Disease Related Vasculopathies and Early Evaluation in a Pediatric Population.

In vivo (Athens, Greece)·2024
Same author

Publisher Correction to: Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma.

Pediatric research·2023
Same author

Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma.

Pediatric research·2023
Same author

Pediatric Patients With Sickle Cell Disease at a Public Hospital: Nutrition, Compliance and Early Experience With L-Glutamine Therapy.

In vivo (Athens, Greece)·2022
Same author

Chemotherapy Can Synergize With Adoptive Immunotherapy to Inhibit Medulloblastoma Growth.

Anticancer research·2022
Same journal

Upregulated Circular RNAs in Gastric Cancer: Target Identification and Tools for Therapeutic Intervention.

Cancer genomics & proteomics·2026
Same journal

Germline Variation in Notch Pathway and Survival After Androgen Deprivation Therapy in Prostate Cancer: Implicating <i>YAP1</i> rs1894116 and Focal Adhesion Signaling.

Cancer genomics & proteomics·2026
Same journal

Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance.

Cancer genomics & proteomics·2026
Same journal

Glucose and Glutamine Define Independent Activation-Braking Metabolic States in Triple Negative Breast Cancer Cells.

Cancer genomics & proteomics·2026
Same journal

Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma.

Cancer genomics & proteomics·2026
Same journal

IL1B-Expressing Exhausted CD4<sup>+</sup> T Cells Are Associated With Disease Aggressiveness in Glioblastoma.

Cancer genomics & proteomics·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.8K

Immunoliposome for Ewing Sarcoma.

Daniel E Panosyan1, William S Panosyan2, Daron S Yacoubian2

  • 1UCLA College of Letters & Science, University of California, Los Angeles, CA, U.S.A.; danielpanosyan@ucla.edu.

Cancer Genomics & Proteomics
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

This study proposes targeted immunoliposomes (IL) for metastatic Ewing sarcoma (EWS) treatment. Anti-CD99 IL loaded with niraparib show potential for selectively destroying EWS cells, offering a novel precision medicine approach.

Keywords:
Ewing sarcomaPARPanti-CD99 antibodyimmunoliposomeniraparib

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.8K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Area of Science:

  • Oncology
  • Nanomedicine
  • Precision Medicine

Background:

  • Metastatic Ewing sarcoma (EWS) has a high mortality rate, necessitating advanced treatment strategies.
  • Precision medicine offers targeted eradication of cancer cells, improving patient outcomes.
  • EWS cells express CD99, a diagnostic marker, making it a target for therapies.

Purpose of the Study:

  • To propose a targeted immunoliposome (IL) capable of selectively binding to and destroying EWS cells.
  • To evaluate the potential of CD99 as a targeting ligand for IL in EWS therapy.
  • To identify a suitable payload for ILs that is more cytotoxic to EWS than normal cells.

Main Methods:

  • Utilized the R2 genomics platform to analyze differential expression of CD99 and PARP1 in EWS and normal tissues.
  • Conducted Kaplan-Meier analysis to determine the prognostic significance of PARP1 expression in EWS.
  • Selected a payload for the proposed IL based on the side-effect profile of PARP inhibitors.

Main Results:

  • EWS samples exhibited higher CD99 expression compared to normal tissues; endothelial cells showed moderate CD99 expression.
  • Recurrent/metastatic EWS demonstrated significantly higher PARP1 expression than primary tumors, correlating with poorer survival rates.
  • Niraparib was selected as the payload due to its favorable side-effect profile, particularly its lower lymphotoxicity.

Conclusions:

  • Targeted immunoliposomes featuring anti-CD99 antibodies and loaded with niraparib represent a promising adjuvant therapy for advanced EWS.
  • The projected 100 nm IL size is expected to enhance vascular permeability and tumor tropism.
  • Further preclinical evaluations are essential to assess potential hematopoietic and endothelial damage.